Welcome to our dedicated page for QT Imaging Holdings news (Ticker: QTI), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QT Imaging Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QT Imaging Holdings's position in the market.
QT Imaging (Nasdaq: QTI) is expected to be added to the Russell Microcap® Index, based on the preliminary additions list dated May 22, 2026. Final inclusion will follow completion of the 2026 Russell indexes reconstitution and, if affirmed, take effect at the U.S. market open on June 29, 2026.
The Russell Microcap Index tracks the microcap segment of the U.S. equity market and is widely used as a benchmark. Membership, according to QT Imaging, can enhance visibility, broaden exposure to institutional investors and index strategies, and brings automatic inclusion in applicable Russell growth and value style indexes.
QT Imaging (Nasdaq: QTI) closed a previously announced underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants) for gross proceeds of about $10 million.
According to QT Imaging, net proceeds will support working capital and general corporate purposes.
QT Imaging (Nasdaq: QTI) priced an underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants) at $5.00 per share, for expected gross proceeds of $10 million before fees.
The offering is expected to close on or about May 18, 2026. According to QT Imaging, net proceeds will support working capital and general corporate purposes, alongside a recently extended senior secured term loan maturity.
QT Imaging (Nasdaq: QTI) reported first quarter 2026 revenue of $6.5 million, up 133% year-over-year, driven by shipment of 13 Breast Acoustic CT scanners. Gross margin was 41%, and net loss narrowed to $3.4 million from $11.1 million.
The company reaffirmed 2026 revenue guidance of ~$39 million, extended its senior secured term loan maturity to March 31, 2029, secured a dedicated Category III CPT code effective January 2027, obtained FDA 510(k) clearance for scanner enhancements, and confirmed UAE regulatory clearance supporting a multiyear agreement for at least 43 scanners totaling over $24 million.
QT Imaging (Nasdaq: QTI) appointed leading breast surgical oncologist Dr. Barry Roseman as Senior Medical Advisor.
He will implement QT Imaging’s radiation-free, 3D breast imaging technology in a high-volume diagnostic and screening center, supporting physician training, workflow integration, patient access, and real-world data collection.
QT Imaging (Nasdaq: QTI) will report financial results for the quarter ended March 31, 2026 after market close on Wednesday, May 13, 2026, and will host an investor conference call the same day at 4:30 p.m. ET / 1:30 p.m. PT.
Participants may pre-register to receive a passcode and PIN; dial-in numbers are provided for U.S. and international callers. A live and archived webcast will be available on the company investor relations calendar.
QT Imaging (Nasdaq: QTI) launched the QT Imaging-Olea Viewer, a unified, multimodality breast imaging viewer developed with Olea Medical. The viewer integrates QTscan data with mammography, DBT, MRI, and ultrasound, supports 3D rendering and future AI/ML tools, and aims to streamline workflow and longitudinal patient review.
The product will be demonstrated at the SBI Breast Imaging Symposium, April 16-19, 2026 in Seattle; the collaboration began in January 2026.
QT Imaging (Nasdaq: QTI) CEO Dr. Raluca Dinu spoke at the inaugural Shiftmakers Gala at Harvard on March 27, 2026, emphasizing early breast cancer detection and the limits of mammography for women with dense breast tissue.
The company said its radiation-free imaging advances will be featured in The Shift to broaden awareness and reach more women and clinicians.
QT Imaging (Nasdaq: QTI) released image reconstruction software version 4.5.0 on April 1, 2026, improving spatial resolution and performance for challenging breast imaging cases.
Enhancements include spatially varying deconvolution, fusion of speed of sound and reflection data, better small-breast reconstruction, and improved assessment with implants.
QT Imaging (Nasdaq: QTI) reported 2025 revenue of $18.9 million, a record aided by shipping 40 scanners and exceeding guidance. The company affirmed 2026 revenue guidance of ~$39 million, citing contracted MOQs and initial QTI Cloud Platform revenue.
Key developments include AMA Category III CPT code approval (effective Jan 1, 2027), FDA 510(k) clearance for an updated scanner configuration, Nasdaq relisting, an $18.2 million private placement, and distribution agreements guaranteeing minimum orders in the UAE totaling 43 scanners (>$24 million revenue).